A recent study published in the Lancet suggests that Alzheimer’s disease could be present and causing subtle memory issues in midlife. Researchers examined whether a blood test could detect the common form of dementia and diagnose individuals many years before noticeable symptoms develop.

The study focused on analyzing the blood of 1,350 individuals without dementia for biomarkers associated with the accumulation of sticky proteins amyloid and tau in the brain, observed in Alzheimer’s patients. Participants, with an average age of 61, who showed high levels of these biomarkers also exhibited lower performance in cognitive tests measuring verbal memory and thinking speed.

Prof. Kristine Yaffe from the University of California emphasized that utilizing blood tests could aid in targeting preventive measures and clinical trials aimed at delaying or preventing dementia onset. The study findings support the idea that Alzheimer’s disease initiates decades before clinical symptoms surface, underscoring the potential importance of plasma biomarkers for early detection.

It remains uncertain whether individuals with amyloid and tau biomarkers will progress to develop and be diagnosed with Alzheimer’s. Researchers are still investigating the role of these proteins in the disease’s progression, as they are found in both Alzheimer’s patients and elderly individuals without dementia symptoms.

Efforts are underway to develop an effective blood test for diagnosing dementia early, before significant memory and cognitive decline. The NHS is currently recruiting participants for a £10 million clinical trial named the ‘Blood Biomarker Challenge’ project, funded by the People’s Postcode Lottery.

Additionally, ongoing research, also featured in the Lancet, proposes a new method of conducting brain scans that can identify tau protein tangles before symptoms manifest. By comparing two imaging agents, the study revealed that the newer agent MK6240 detected more tau-positive cases in early regions compared to the established Flortaucipir tracer.

Dr. Jacqui Hanley from Alzheimer’s Research UK noted the significance of these studies in advancing early detection of Alzheimer’s-related changes, which could offer opportunities for participation in new treatment studies and timely access to disease-modifying therapies. With nearly one million Britons currently affected by dementia, the urgency to enhance diagnostic capabilities and treatment options is evident.